The cell-biological program termed the epithelial-to-mesenchymal transition (EMT) has been invoked as a critical component of the meta static process. Contrastingly, Fischer et al. 1 recently reported that in two genetically engineered mouse models of mammary tumour deve lopment, carcinoma cells could metastasize without activating EMT programs. However, as detailed below, we find their evidence that EMT programs were not expressed in these primary tumours to be insufficient. Therefore, the contribution of EMT to carcinoma meta stasis could not be ruled out in their analysis. There is a Reply to this Comment by Fischer, K. R. et al. Nature 547, http://dx.doi.org/10.1038/nature22817 (2017).
It has been well-established that the EMT is not a single, stereotypical program [2] [3] [4] . Instead, it represents a group of related cell-biological programs, each of which confers certain mesenchymal traits on epithelial cells. Its variability stems from the facts that (1) it can be induced by expression of multiple alternative transcription factors [5] [6] [7] [8] [9] ; (2) cells activating an EMT program often proceed only part-way towards a fully mesenchymal state, acquiring only a fraction of various mesenchymal markers 2, 10, 11 and such partial and reversible activation of EMT has been shown to be critical for metastasis [12] [13] [14] [15] ; and (3) EMT programs may be manifested in different ways in different tissues [2] [3] [4] 12 . These considerations help to illuminate the EMT programs analysed in the publications by Fischer et al. 1 , who concluded that metastasis from primary tumours occurred in the absence of EMT activation.
Fischer et al. 1 employed the Cre/CreER lineage-tracing method to track carcinoma cells that have undergone EMT activation. In such a genetic tracing protocol, the promoter of interest drives the expression of the Cre recombinase, which in turn inflicts a stable genetic mark on the genome of a cell and its lineal descendants. A derivation of this basic protocol involves a CreER protein, which only functions when a ligand of the oestrogen receptor (ER), in this case tamoxifen, is present. Hence, the marking of a cell depends on the concomitant presence of CreER expression and experimentally supplemented tamoxifen. In the present case, the authors used a Cre-activatable GFP transgene; accordingly, transient actions of Cre/CreER would permanently turn off an RFP marker and activate a GFP reporter. By monitoring the expression of GFP, Fischer et al. 1 would therefore be able to determine whether an ancestor of these cells had expressed Cre/CreER.
In order for the lineage tracing system to effectively mark carcinoma cells that have undergone EMT activation, it needs to meet, in our view, at least two criteria (Fig. 1a) . First, the Cre/CreER driver needs to be expressed in most if not all of the cells that transiently undergo EMT activation. Second, once expressed, the Cre/CreER protein needs to activate the GFP reporter in most if not all of the carcinoma cells where Cre/CreER is expressed.
Fischer et al. 1 chose to use transgenic Cre/CreER lines driven by the promoters of two genes, Fsp1 and Vim, that are known to be expressed in certain versions of the EMT program. For most of their analyses, they used an Fsp1-cre transgene. The authors portrayed Fsp1 as a "critical gatekeeping gene" of EMT initiation, based on a publication showing that Fsp1 is required in order for renal proximal tubular epithelial cells to undergo an EMT in vitro in response to TGFβ 16 . If this portrayal of the gatekeeper role of Fsp1 were accurate, this would qualify its expression as a sensitive indicator of EMT activation. However, given the variable manifestations of the EMT program in various tissues [2] [3] [4] 14 , there is no reason to believe that a marker of EMT activation in renal tubular cells will serve as a useful indicator in unrelated tissues, in this case the mammary epithelium. In fact, there is abundant evidence that Fsp1 is not an integral component of all EMT programs 17 , as Fsp1-knockout mice are capable of undergoing all stages of developmental EMT and are viable and fertile 18 . Moreover, in our own studies, while we could indeed , when we employed immunofluorescence staining to investigate the expression of Fsp1, we found that it was only expressed in a very small fraction of carcinoma cells that had activated versions of the EMT program as indicated by the expression of the Snail and Zeb1 EMT transcription factors, known master regulators of EMT programs (Fig. 1b, c and Extended Data Fig. 1) . Hence, we think that the authors' conclusion 1 that EMT did not occur in the metastatic cells that failed to undergo Fsp1-Cre-mediated GFP activation cannot be sustained.
Fischer et al. 1 also used a second transgene, Vim-creER, in which expression of the tamoxifen-activated CreER recombinase is driven by a Vim promoter. The authors administered tamoxifen three times a week to activate the CreER recombinase following formation of primary tumours. However, this genetic tracing approach also fails to meet the two criteria we proposed above. First, vimentin is expressed weakly or undetectably in carcinoma cells that have, by a number of other criteria, indeed activated versions of the EMT program in the MMTV-PyMT model (Fig. 1b, c and Extended Data Fig. 1 ). Second, the recombination efficiency of the Vim-CreER tracing system is far from complete. As is evident in extended data fig. 3 of Fischer et al. 1 , a large fraction of tumour-associated stromal cells that express vimentin at high levels remained GFP-negative even after weeks of tamoxifen administration. Hence, once again the absence of GFPlabelled cells in the metastases could not be used to conclude that versions of the EMT program had not been expressed in metastasisinitiating cells.
Fischer et al. 1 also undertook to suppress the EMT program in primary carcinoma cells through forced expression of miR-200, which can directly inhibit expression of the Zeb1 EMT transcription factor. The authors observed that forced miR-200 expression failed to suppress metastasis and concluded once again that activation of an EMT program was not involved in the metastatic dissemination of primary carcinoma cells. However, in addition to suppressing Zeb1, miR-200 is known to have EMT-independent functions in promoting metastatic colonization. miR-200 can directly suppress expression of Sec23, thereby dampening the secretion of metastasis-suppressing proteins such as TINAGL1 19 . In fact, a previous report has demonstrated that the metastasis-promoting function of miR-200 is able to counterbalance its potential anti-metastatic effects 19 . Furthermore, in the paper by Fischer et al. 1 , it was apparent that the observed EMT suppression by miR-200 was very incomplete, resulting in only a <10% reduction of N-cadherin and an approximate twofold reduction of Twist EMT transcription factor expression; this indicated that various versions of the EMT program could still operate under this experimental condition.
Given the potential pitfalls in the experimental design and observations, we conclude that the Fischer et al. 1 report was insufficient to rule out the contribution of EMT to metastasis. Moreover, in the same PyMT mouse model of breast cancer formation, Cre-mediated genetic deletion of Snail in tumour cells almost completely abolished lung metastasis, reducing it from an average of 200 lung metastases to less than 10 lesions 14 . Furthermore, PCR analysis of the genomic DNA extracted from the remaining metastatic lesions failed to detect the Cre-recombined Snail allele, indicating that these remaining metastases probably arose due to incomplete deletion of the Snail gene in primary tumour cells 14 . These results were confirmed recently by Ni et al. 20 ; together these two studies provide direct genetic evidence of a critical role of the EMT transcription factor Snail in breast cancer metastasis. Thus, we believe that the notion that the observed metastatic dissemination of mammary tumours does indeed depend on EMT programs continues to be a viable mechanism to explain metastatic dissemination.
Methods

Mammary tumours from Snai1
YFP/+ ;MMTV-PyMT 5 animals were fixed in 10% formalin and paraffin sectioned. Tumour sections were deparaffinized and antigen retrieval performed with Nuclear Decloaker (Biocare Medical). Sections were blocked with 1% normal donkey serum in PBST (PBS with 0.3% Triton X-100), incubated with primary antibody at 4 °C overnight, washed with PBS, incubated with secondary antibodies (Biotium) and DAPI, washed with PBS, and mounted in ProLong Gold antifade reagent (Invitrogen P36930). For anti-Zeb1 immunofluorescence, the staining was amplified with the TSA Plus System (Perkin Elmer) following the manufacturer's instructions. Stained sections were imaged using the Zeiss LSM700 confocal microscope and analysed with Zen software. Data availability. All data are available from the corresponding author upon reasonable request. In our original paper, we demonstrated, using a novel lineage tracing reporter system, that the epithelial-to-mesenchymal transition (EMT) is not necessary for metastasis but contributes to chemoresistance , including concepts such as "various versions of EMT", "certain versions of EMT" and "partial" EMT. In our view, these concepts are not well-defined by molecular characterization, nor is there direct evidence of their requirement in metastasis; thus we disagree that they can be used to interpret our findings. Ye et al. 2 also suggest that Fsp1-Cre or Vim-CreER are inadequate in reporting EMT, and that miR-200 overexpression may not have inhibited EMT. Here, we wish to provide clarity regarding the tools we have used in our study.
Xin Ye
Vim and Fsp1 promoters were selected as they are sentinels of EMT activation. They are commonly accepted mesenchymal markers, which have been employed in many published reports 4, 5 . Ye et al. 2 provided immunofluorescence images to indicate a lack of Fsp1 and vimentin in Snail + or Zeb1 + cytokeratin + 'EMT' cells. While the sensitivity and specificity of the antibodies used may contribute to the interpretation of immunofluorescence results, it is important to also recognize that the expression of one EMT transcription factor is not sufficient to conclude that EMT-a process characterized by extensive morphologic and phenotypic changes-has occurred. In addition, a recent report 6 noted vimentin upregulation (>6-fold) in Snail + cells (figure 3e in ref. 6) , in agreement with our data, although we think it is unclear whether the Snail-YFP + cells detected in the primary tumours are the true initiators of metastasis in vivo.
Ye et al. 2 referenced a study showing that genetic deletion of Snail impaired lung metastasis 7 . However, a more recent report showed that the major impact of Snai1 knockout was the delayed onset of primary tumour growth 8 . Snail was highly expressed in preneoplastic lesions, and worked as a p53 suppressor that directly impacted cell proliferation in tumour-initiating cells. In pancreatic cancer models, Zheng et al. found that knockout of Twist or Snail had no effect on metastasis 9 . These inconsistent results further justify our decision to utilize downstream markers of EMT for our study.
We extensively characterized the fidelity and efficiency of both Fsp1-Cre and Vim-CreER in reporting the EMT lineage in primary tumours, circulation and early metastatic lungs 1 . The activation of Fsp1-Cre, which led to the switch from RFP to GFP, was associated with a broad panel of EMT marker changes in the tumour cells both in vitro and in vivo. This includes analysis of the EMT transcription factor Zeb1. Quantitative immunofluorescence of the orthotopic tumours revealed Zeb1 expression in GFP + cells, and not in RFP + cells (Fig. 1) ; reinforcing the precision of our EMT lineage tracing model wherein no EMT cells were detected in the RFP + population.
Ye et al. 2 question the recombination efficiency of Vim-CreER. However, we reported the co-localization of vimentin with GFP + , but not RFP + tumour cells in the Vim-CreER model (extended data fig. 6a in ref. 1) , indicating the presence of GFP + EMT cells in the primary tumours. The GFP + EMT cells constitute 4.46 ± 1.0% of the total primary tumour cells in the Vim-CreER model 1 . Importantly, none of the metastases we observed were derived from these GFP + EMT cells. They also suggest that in the miR-200 studies, suppression of EMT was incomplete, citing a <10% reduction in N-cadherin and approximate twofold reduction in Twist. However, in extended data fig. 7d of ref. 1, we showed that E-cadherin and occludin increased 8-10-fold and vimentin and Fsp1 decreased by 5-20-fold. Notably, we reported the statistically significant suppression of the transcription factors defined as 'EMT master regulators' Zeb1/2 (7.1-and 5.2-fold reduction, respectively) and Snail1 and Snail2 (4.2-and 7.8-fold reduction, respectively). Yet, this had no impact on metastasis formation in our model. Ye et al. 2 also postulated that the metastasispromoting function of miR-200 would negate the anti-metastatic effects of EMT suppression. In our view, this runs counter to the theory that EMT is vital for metastasis. If the suppression of EMT is able to be compensated for by a process, "that goes beyond [miR-200's] regulation of E-cadherin and epithelial phenotype" 10 , then EMT is not required for metastasis; in agreement with our findings.
Based on our EMT lineage tracing models, EMT is not required to generate distant metastasis. However, we confirmed a role for EMT in metastatic recurrence in the context of chemotherapy, consistent with findings in a model of pancreatic cancer 9 . We believe that future studies employing innovative technologies will continue to investigate the role of EMT; however, alternative modes of tumour dissemination such as collective or cluster-based migration and/or invasion 11, 12 should be considered.
This Reply was prepared by the authors who made major concept contributions to the original paper 1 , while other authors who made technical and material contributions did not participate. 
